8-K: Acelyrin Announces Positive Phase 2 Data and Phase 3 Trial Design for Lonigutamab in Thyroid Eye Disease

Acelyrin reported positive Phase 2 data for lonigutamab in thyroid eye disease, showing improvements across key metrics, and detailed the design of its Phase 3 program.

Summary

• Acelyrin announced additional Phase 2 data for lonigutamab, an investigational treatment for thyroid eye disease (TED), demonstrating clinically meaningful improvements in proptosis, Clinical Activity Score (CAS), diplopia, and quality of life.
• The data showed significant proptosis response with a 50mg loading dose and 25mg weekly subcutaneous dose, and efficacy at lower exposure levels compared to intravenously-administered anti-IGF-1R agents.
• No cases of hearing impairment, hyperglycemia, or menstrual disorders were reported in TED patients at any dose level.
• Pharmacokinetic data indicated that a 100mg loading dose achieved target therapeutic concentrations within days.
• The Phase 3 LONGITUDE program will consist of two global, double-masked, placebo-controlled trials (LONGITUDE-1 and LONGITUDE-2) involving approximately 350 patients.
• Patients will be randomized 2:1 to lonigutamab or placebo for the first 24 weeks, with a primary endpoint of proptosis response rate at 24 weeks.
• All patients will receive lonigutamab from week 24 to week 52.
• LONGITUDE-1 will enroll a minimum of 81 active TED patients, while LONGITUDE-2 will include both active and chronic TED patients.
• The company expects to initiate the Phase 3 program in the first quarter of 2025 and anticipates topline data in the second half of 2026.

Sentiment

Score: 8

Explanation: The document presents positive Phase 2 data and a well-defined Phase 3 trial design, indicating strong potential for lonigutamab. The absence of significant safety concerns and the subcutaneous administration are also positive factors.

Positives

• Lonigutamab showed clinically meaningful and competitive improvements across all manifestations of TED.
• The subcutaneous administration of lonigutamab is a positive development.
• The absence of reported hearing impairment, hyperglycemia, and menstrual disorders is encouraging.
• The Phase 3 trial design has been aligned with the FDA.
• The study design includes a longer term treatment period of 52 weeks.

Risks

• The company's actual results may differ materially from forward-looking statements due to risks and uncertainties.
• Risks include the successful completion of development and regulatory activities, maintaining intellectual property protection, and securing adequate supply of product candidates.
• Other risks include potential delays, legal proceedings, macroeconomic conditions, and market volatility.

Future Outlook

The company anticipates initiating the Phase 3 LONGITUDE program in the first quarter of 2025 and expects topline data from the trial in the second half of 2026.

Industry Context

This announcement is significant in the context of the competitive landscape for thyroid eye disease treatments, particularly given the positive results and the subcutaneous administration of lonigutamab, which could offer advantages over existing intravenous therapies.

Comparison to Industry Standards

• The reported efficacy of lonigutamab, particularly the proptosis response, will be closely compared to existing treatments like Tepezza (teprotumumab), which is an intravenously administered anti-IGF-1R antibody.
• The subcutaneous administration of lonigutamab is a potential advantage over Tepezza, which requires intravenous infusions.
• The Phase 3 trial design, including the 24-week primary endpoint and the 52-week treatment period, is consistent with industry standards for TED clinical trials.
• The inclusion of both active and chronic TED patients in the trials is also a common practice in the field.

Stakeholder Impact

• Shareholders will likely react positively to the promising clinical data and the advancement of the Phase 3 program.
• Patients with TED may benefit from a new treatment option with potentially improved efficacy and a more convenient administration method.
• The company's employees will be involved in the execution of the Phase 3 trials.

Next Steps

• Initiate the Phase 3 LONGITUDE program in the first quarter of 2025.
• Conduct the LONGITUDE-1 and LONGITUDE-2 trials.
• Collect and analyze data from the Phase 3 trials.
• Report topline data from the Phase 3 trial in the second half of 2026.

Key Dates

Keywords

lonigutamab, thyroid eye disease, TED, Phase 3 trial, proptosis, clinical activity score, CAS, diplopia, LONGITUDE program, subcutaneous, FDA